Partial OSKM Reprogramming — Gene Therapy & Genetic Interventions
Transient expression of Yamanaka factors (Oct4, Sox2, Klf4, c-Myc) to reverse epigenetic age without dedifferentiation.
Overview
Partial cellular reprogramming uses pulsed, transient expression of Yamanaka factors (OSKM) to reverse age-associated epigenetic changes without fully dedifferentiating cells to pluripotency. Landmark studies by Ocampo et al. (2016) demonstrated that cyclic OSKM expression in progeroid mice extended lifespan by 33% and restored youthful gene expression patterns. Subsequent work showed epigenetic age reversal in wild-type aged mice, with improved tissue function in muscle, pancreas, and optic nerve. Altos Labs, Turn Biotechnologies, and Shift Bioscience are developing clinical translation strategies.
Indications
- Epigenetic age reversal
- Age-related tissue dysfunction
- Optic nerve regeneration (preclinical)
- Muscle regeneration in aging
- Whole-organism rejuvenation (preclinical)
Mechanism of Action
Transient expression of Oct4, Sox2, Klf4, and c-Myc opens chromatin and activates reprogramming networks
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| AAV-inducible OSKM | Study-specific | Cyclic: 2 days on / 5 days off | Doxycycline-inducible system for temporal control |
| mRNA-OSKM cocktail | Study-specific | Pulsed delivery cycles | Non-integrating approach; Turn Bio mRNA platform |
Evidence Grade
GRADE C
Safety & Contraindications
- Teratoma formation risk if reprogramming is not precisely controlled
- c-Myc is a known oncogene; OSK (without Myc) variants are under investigation
- Dosing window between rejuvenation and dedifferentiation is narrow
- Tissue-specific effects may vary; systemic delivery carries higher risk
- All approaches are preclinical; no human clinical trials
- Delivery method (AAV, mRNA, small molecules) significantly affects risk profile